These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
3. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Shepherd J; Betteridge J; Van Gaal L; Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866 [TBL] [Abstract][Full Text] [Related]
4. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. Hoerger TJ; Ahmann AJ J Manag Care Pharm; 2008 Feb; 14(1 Suppl C):S2-14; quiz 15-6. PubMed ID: 18240890 [TBL] [Abstract][Full Text] [Related]
5. Successful control of dyslipidemia in patients with metabolic syndrome: focus on lifestyle changes. Stone NJ Clin Cornerstone; 2006; 8 Suppl 1():S15-20. PubMed ID: 16903165 [TBL] [Abstract][Full Text] [Related]
6. Nurse health and lifestyle modification versus standard care in 40 to 70 year old regional adults: study protocol of the Management to Optimise Diabetes and mEtabolic syndrome Risk reduction via Nurse-led intervention (MODERN) randomized controlled trial. Carrington MJ; Zimmet P BMC Health Serv Res; 2017 Dec; 17(1):813. PubMed ID: 29212477 [TBL] [Abstract][Full Text] [Related]
7. Lifestyle modifications for the prevention and treatment of cardiovascular disease: an evidence-based approach. Harris GD; White RD Mo Med; 2004; 101(3):222-6. PubMed ID: 15311577 [TBL] [Abstract][Full Text] [Related]
13. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Scott R; O'Brien R; Fulcher G; Pardy C; D'Emden M; Tse D; Taskinen MR; Ehnholm C; Keech A; Diabetes Care; 2009 Mar; 32(3):493-8. PubMed ID: 18984774 [TBL] [Abstract][Full Text] [Related]
14. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Didangelos TP; Thanopoulou AK; Bousboulas SH; Sambanis CL; Athyros VG; Spanou EA; Dimitriou KC; Pappas SI; Karamanos BG; Karamitsos DT Curr Med Res Opin; 2004 Sep; 20(9):1393-401. PubMed ID: 15383188 [TBL] [Abstract][Full Text] [Related]
15. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Florkowski CM Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Ovalle F Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987 [TBL] [Abstract][Full Text] [Related]
20. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Bestermann W; Houston MC; Basile J; Egan B; Ferrario CM; Lackland D; Hawkins RG; Reed J; Rogers P; Wise D; Moore MA Am J Med Sci; 2005 Jun; 329(6):292-305. PubMed ID: 15958871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]